• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

GRAFT SURVIVAL

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

ACE2 LISTERIA MONOCYTOGENES AUTOPHAGY ANGIOTENSIN II IFNG TNF IMMUNE RESPONSE CD4 NEUTROPHILS RHEUMATOID ARTHRITIS IL6 PSEUDOMONAS AERUGINOSA INSULIN ACE AGING SARS-COV-2 PD-1 IMMUNITY COGNITION CELL PROLIFERATION COVID-19 COAGULATION INFLAMMATORY RESPONSE CANDIDA ALBICANS TMPRSS2 INFLAMMATION CASP3 ALBUMIN RAS ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS INTERFERON LACTATE DEHYDROGENASE IL1B NFKB1 METFORMIN IL2 CANCER MYALGIA APOPTOTIC PROCESS HELICOBACTER PYLORI ALZHEIMER'S DISEASE PARKINSON DISEASE IL10 CELL DIFFERENTIATION

© 2021 Biovista Vizit All Rights Reserved.